Clinical Trial Update: Effects of FT011 in Systemic Sclerosis [Phase 2]

View source ↗

Summary

Phase 2 trial update on FT011 for systemic sclerosis (scleroderma) has been completed with results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Scleroderma Diffuse
• Sclerosis Systemic
• Systemic Sclerosis

Drugs mentioned

• FT011

Snippet

Sponsor: Certa Therapeutics | Conditions: Scleroderma, Systemic, Scleroderma, Diffuse | Phase 2 | Status: COMPLETED | Results posted: 2023-12-20